Abstract:Human defensins are at the forefront of the host responses to HIV and other pathogens in mucosal tissues. However, their ability to inactivate HIV in the bloodstream has been questioned due to the antagonistic effect of serum. In this study, we have examined the effect of sub-inhibitory concentrations of human alpha-defensin HNP-1 on the kinetics of early steps of fusion between HIV-1 and target cells in the presence of serum. Direct measurements of HIV-cell fusion using an enzymatic assay revealed that, in spite of the modest effect on the extent of fusion, HNP-1 prolonged the exposure of functionally important transitional epitopes of HIV-1 gp41 on the cell surface. The increased lifetime of gp41 intermediates in the presence of defensin was caused by a delay in the post-coreceptor binding steps of HIV-1 entry that correlated with the marked enhancement of the virus' sensitivity to neutralizing anti-gp41 antibodies. By contrast, the activity of antibodies to gp120 was not affected. HNP-1 appeared to specifically potentiate antibodies and peptides targeting the first heptad repeat domain of gp41, while its effect on inhibitors and antibodies to other gp41 domains was less prominent. Sub-inhibitory concentrations of HNP-1 also promoted inhibition of HIV-1 entry into peripheral blood mononuclear cells by antibodies and, more importantly, by HIV-1 immune serum. Our findings demonstrate that: (i) sub-inhibitory doses of HNP-1 potently enhance the activity of a number of anti-gp41 antibodies and peptide inhibitors, apparently by prolonging the lifetime of gp41 intermediates; and (ii) the efficiency of HIV-1 fusion inhibitors and neutralizing antibodies is kinetically restricted. This study thus reveals an important role of alpha-defensin in enhancing adaptive immune responses to HIV-1 infection and suggests future strategies to augment these responses.

Human α- and β-Defensins Block Multiple Steps in Herpes Simplex Virus Infection

Enhancement of Antiviral Activity of Human Alpha-Defensin 5 Against Herpes Simplex Virus 2 by Arginine Mutagenesis at Adaptive Evolution Sites

Delineation of Interfaces on Human Alpha-Defensins Critical for Human Adenovirus and Human Papillomavirus Inhibition

Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry

Critical Determinants of Human Α-Defensin 5 Activity Against Non-enveloped Viruses

Human defensins 5 and 6 enhance HIV-1 infectivity through promoting HIV attachment

Multifaceted Mechanisms of HIV-1 Entry Inhibition by Human Α-Defensin.

Human Α‐defensins Are Immune‐related Kv1.3 Channel Inhibitors: New Support for Their Roles in Adaptive Immunity

Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection.

Mucosal human defensins 5 and 6 antagonize the anti-HIV activity of candidate polyanion microbicides.

Human Alpha-Defensins Inhibit Hemolysis Mediated by Cholesterol-Dependent Cytolysins

Key Determinants of Human α-Defensin 5 and 6 for Enhancement of HIV Infectivity.

Crystal structures of human α-defensins HNP4, HD5, and HD6

Human Beta-Defensin 2 and 3 Inhibit HIV-1 Replication in Macrophages

Inhibition of herpes simplex virus type 1 infection by cationic beta-peptides

High-level expression of glycoprotein D by a dominant-negative HSV-1 virus augments its efficacy as a vaccine against HSV-1 infection.

Human Α-Defensin 6 Promotes Mucosal Innate Immunity Through Self-Assembled Peptide Nanonets.

Harringtonine Inhibits Herpes Simplex Virus Type 1 Infection by Reducing Herpes Virus Entry Mediator Expression

Antibacterial Activity and Specificity of the Six Human Α-Defensins

Human Beta-Defensins Induce APOBEC3G Expression by Interacting with Chemokine Receptors, Protecting Highly Susceptible Cells from HIV Infection

Sub-inhibitory concentrations of human α-defensin potentiate neutralizing antibodies against HIV-1 gp41 pre-hairpin intermediates in the presence of serum.